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The acceleration of biopharmaceutical process development is difficult when traditional experience-based 
sequential approaches are used. As a result, fully optimized and well understood cell culture processes prior to 
scale-up are rare.  Here we show that an accurate, scalable and simple model able to predict cell growth, cell 
metabolism, titer and some product quality attributes will significantly accelerate process development, improve 
process development outcomes and reduce development and production costs.  
 
In this paper we will present a simple systematic modeling methodology to 
study and predict fed-batch cell culture performance [1]. We will also show 
that this approach can be applied to the optimization of perfusion processes. 
Only a limited number of parameters need to be identified based on 
experimental results, which means that for each production process to be 
modeled, a minimal number of small scale bioreactor runs need to be 
performed before switching to in silico process development. We will show 
that this approach can accurately predict process performance both at small 
and large scale. Furthermore, various feeding strategies could be tested and 
optimized in silico. Moreover, the model was able to predict the impact of the 
depletion of essential metabolites on the specific productivity and also the 
impact of intracellular metabolite pools on cell growth. 
  
In a second step, the model was extended and applied to critical product 
quality attributes such as charge variants. This modeling approach shed 
further light on the impact of the feeding strategy on product quality. For 
instance, we will show that the total quantity of specific metabolites used 
throughout the bioreactor production process controls charge variants 
distribution, whereas within a given concentration range the daily 
concentration of these same metabolites is not predictive. To the best of our 
knowledge, this is the first study that shows that it is the total quantity of 
metabolites used that impacts mAb microheterogeneity.  
 
Finally, the model was also applied to the development of continuous and 
hybrid/intensified production processes. The perfusion rate was controlled 
daily using the model calibrated with fed-batch production data. Moreover, a 
concentrated perfusion medium was developed and optimized in silico.  
 
In summary, our modeling methodology provides a much better insight into the impact of process parameters on 
production yields and product quality, thus improving process understanding and control as well as accelerating 
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Figure 2 – Comparison of 
experimental with predicted 
acidic peak group (APG) 
Figure 1 – Comparison of 
experimental with predicted 
mAb titers 
